Alessandra M. Contino
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Corrigendum: Improved memory CD8 T cell response to delayed vaccine boost is associated with a distinct molecular signature.
Journal: Frontiers in immunology
Published: April 03, 2023
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
Journal: Cell reports. Medicine
Published: October 21, 2022
Improved memory CD8 T cell response to delayed vaccine boost is associated with a distinct molecular signature.
Journal: Frontiers in immunology
Published: September 13, 2022
Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results.
Journal: NPJ vaccines
Published: February 18, 2022
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults.
Journal: Science translational medicine
Published: October 26, 2021
Correction: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.
Journal: PLoS neglected tropical diseases
Published: April 13, 2021
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 06, 2020
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
Journal: Science translational medicine
Published: October 08, 2019
A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.
Journal: PLoS neglected tropical diseases
Published: September 27, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026